Page last updated: 2024-12-04

succinic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Succinic Acid: A water-soluble, colorless crystal with an acid taste that is used as a chemical intermediate, in medicine, the manufacture of lacquers, and to make perfume esters. It is also used in foods as a sequestrant, buffer, and a neutralizing agent. (Hawley's Condensed Chemical Dictionary, 12th ed, p1099; McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed, p1851) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

succinic acid : An alpha,omega-dicarboxylic acid resulting from the formal oxidation of each of the terminal methyl groups of butane to the corresponding carboxy group. It is an intermediate metabolite in the citric acid cycle. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID1110
CHEMBL ID576
CHEBI ID15741
MeSH IDM0029380

Synonyms (161)

Synonym
succinate, 9
bdbm26121
succinic acid, 6
e363
acidum succinicum
butandisaeure
hooc-ch2-ch2-cooh
CHEBI:15741 ,
acide succinique
bernsteinsaeure
acide butanedioique
butanedioic acid diammonium salt
nsc-25949
NSC25949 ,
LMFA01170043
succinic acid, puriss. p.a., acs reagent, >=99.5% (t)
SIN ,
wormwood acid
asuccin
1,2-ethanedicarboxylic acid
katasuccin
butanedioic acid
bernsteinsaure
dihydrofumaric acid
nsc-106449
nsc106449
110-15-6
succinic acid
amber acid
wormwood
wln: qv2vq
inchi=1/c4h6o4/c5-3(6)1-2-4(7)8/h1-2h2,(h,5,6)(h,7,8
1,4-butanedioic acid (succinic acid)
ethylene dicarboxylic acid
a 12084
butanedioic acid (9ci)
ai3-06297
hsdb 791
succinic acid (8ci)
1,4-butanedioic acid
succ
SUC ,
ethylenesuccinic acid
C00042
butanedionic acid
succinic acid, bioxtra, >=99.0%
succinic acid, reagentplus(r), >=99.0%
succinic acid, natural
succinic acid, fcc
succinic acid, bioreagent, suitable for cell culture, suitable for insect cell culture
NCGC00159372-02
1CZE
DB00139
succinic acid, acs reagent, >=99.0%
NCGC00159372-03
einecs 203-740-4
bernsteinsaure [german]
brn 1754069
kyselina jantarova [czech]
nsc 106449
1,2 ethanedicarboxylic acid
1,4 butanedioic acid
STK387105
37E8FFFB-70DA-4399-B724-476BD8715EF0
AKOS000118899
fema no. 4719
succinicum acidum
CHEMBL576
BMSE000183
FT-0652509
S0100
NCGC00159372-04
NCGC00159372-05
BBL002473
unii-ab6mnq6j6l
kyselina jantarova
4-02-00-01908 (beilstein handbook reference)
ec 203-740-4
ab6mnq6j6l ,
succinic acid [nf]
dtxcid303602
tox21_303247
NCGC00257092-01
dtxsid6023602 ,
cas-110-15-6
tox21_201918
tox21_111612
NCGC00259467-01
BMSE000968
succinellite
ethylene succinic acid
ethanedicarboxylic acid
sal succini
S3791
butane diacid
succinic acid [who-dd]
adipic acid impurity b [ep impurity]
succinicum acidum [hpus]
succinic acid [mi]
succinic acid [fcc]
succinic acid [hsdb]
succinic acid [usp impurity]
succinic acid [vandf]
succinic acid [ii]
succinic acid [mart.]
succinic acid [usp-rs]
succinic acid [inci]
4LH2
butanedioic acid-13c4
butanedioic acid-1,4-13c2
gtpl3637
BP-21128
AB01332192-02
tox21_111612_1
Z57127453
mfcd00002789
succinicate
J-002386
F2191-0239
succinic acid, anhydrous, free-flowing, redi-dri(tm), acs reagent, >=99.0%
succinic acid, matrix substance for maldi-ms, >=99.5% (t), ultra pure
1,4-butandioic acid
succinicacid(industrialgrade&foodgrade)
SR-01000944556-2
sr-01000944556
succinic acid, saj special grade, >=99.5%
succinic acid, purum p.a., >=99.0% (t)
succinic acid, 99%
succinic acid, united states pharmacopeia (usp) reference standard
succinic acid, saj first grade, >=99.0%
succinic acid, certified reference material, tracecert(r)
succinic acid, acs grade
succinic acid, vetec(tm) reagent grade, 98%
succinic acid, pharmaceutical secondary standard; certified reference material
succinic acid, p.a., acs reagent, 99.0%
succinic acid, >=99%, fcc, fg
succinic acid; butanedioic acid
CS-0008946
1,4-butanedioate
dihydrofumarate
1,2-ethanedicarboxylate
HY-N0420
FT-0773657
butandisaure
succinic acide,(s)
Q213050
A14596
EN300-17990
succinic-acid
succinic acid high purity grade 2.5kg
STR02803
HMS3885O04
CCG-266069
D85169
NCGC00159372-06
26776-24-9
succinic acid (butanedioic acid)
adipic acid impurity b (ep impurity)
succinic acid (usp impurity)
succinic acid (ii)
succinic acid (mart.)

Research Excerpts

Overview

Succinic acid (SA) is a four-carbon dicarboxylic acid, which has attracted much interest due to its abroad usage as a precursor of many industrially important chemicals in the food, chemicals, and pharmaceutical industries. It is a platform chemical that plays an important role as precursor for the synthesis of many valuable bio-based chemicals.

ExcerptReferenceRelevance
"Succinic acid is a focal point for cancer treatments not only for its apoptotic success on cancer cells but also for its capacity to be metabolically active for humans."( The apoptotic efficacy of succinic acid on renal cancer cell lines.
Cakmakoglu, B; Ertugrul, B; Iplik, ES; Kasarci, G, 2021
)
1.64
"Succinic acid (SA) is a top platform chemical obtainable from biomass. "( Process optimisation for production and recovery of succinic acid using xylose-rich hydrolysates by Actinobacillus succinogenes.
Binod, P; Castro, E; Coulon, F; Durgapal, S; Kumar, G; Kumar, V; Narisetty, V; Oreoluwa Jokodola, E; Rajesh Banu, J; Sindhu, R, 2022
)
2.41
"Succinic acid is a potential biomarker of SDH related pathologies for diagnostic, evaluation of treatment response and follow-up of the disease."( Quantification of succinic acid levels, linked to succinate dehydrogenase (SDH) dysfunctions, by an automated and fully validated liquid chromatography tandem mass spectrometry method suitable for multi-matrix applications.
Blondel, L; Broutin, S; Lamy, C; Mansard, C; Mercier, L; Paci, A, 2022
)
1.78
"Succinic acid is a valuable bulk chemical, which has been extensively applied in food, medicine, surfactants and biodegradable plastics industries. "( Recent progress on bio-succinic acid production from lignocellulosic biomass.
Cong, Y; Gao, H; Jiang, M; Li, J; Lu, J; Xin, F; Xu, H; Zhang, W; Zhou, D, 2021
)
2.37
"Succinic acid (SA) is a well-established chemical building block. "( Biosuccinic Acid from Lignocellulosic-Based Hexoses and Pentoses by Actinobacillus succinogenes: Characterization of the Conversion Process.
Ferone, M; Marzocchella, A; Olivieri, G; Raganati, F; Salatino, P, 2017
)
2.52
"Succinic acid is a four-carbon dicarboxylic acid, which has attracted much interest due to its abroad usage as a precursor of many industrially important chemicals in the food, chemicals, and pharmaceutical industries. "( Progress of succinic acid production from renewable resources: Metabolic and fermentative strategies.
Dong, W; Jia, H; Jiang, M; Liang, L; Liu, R; Ma, J; Wu, M; Xin, F; Zhang, W, 2017
)
2.28
"Succinic acid is a platform chemical that plays an important role as precursor for the synthesis of many valuable bio-based chemicals. "( Genomic and transcriptomic analysis of Saccharomyces cerevisiae isolates with focus in succinic acid production.
Bessa, D; Franco-Duarte, R; Gonçalves, F; Martins, R; Pais, C; Sampaio, P; Schuller, D; Silva-Ferreira, AC, 2017
)
2.12
"Succinic acid is a platform chemical of recognized industrial value and accordingly faces a continuous challenge to enable manufacturing from most attractive raw materials. "( Bio-based succinate from sucrose: High-resolution
Becker, J; Cahoreau, E; Haefner, S; Krawczyk, J; Lange, A; Portais, JC; Schröder, H; Schulze, D; Wittmann, C; Zelder, O, 2017
)
1.9
"Succinic acid is a high value-added organic acid widely used in food, chemical and pesticide industries. "( [Control of acetic acid metabolism of recombinant Yarrowia lipolytica for efficient succinic acid production].
Gao, C; Zheng, Y, 2018
)
2.15
"Succinic acid is an important platform chemical for synthesis of C4 compounds. "( Enhanced succinic acid production by Actinobacillus succinogenes after genome shuffling.
Sun, Z; Xu, Y; Yan, Q; Zhang, K; Zheng, P, 2013
)
2.25
"Succinic acid is a specialty chemical having numerous applications in industrial, pharmaceutical and food uses. "( Metabolic engineering of Escherichia coli to minimize byproduct formate and improving succinate productivity through increasing NADH availability by heterologous expression of NAD(+)-dependent formate dehydrogenase.
Balzer, GJ; Bennett, GN; San, KY; Thakker, C, 2013
)
1.83
"Succinic acid is an important C4 platform chemical in the synthesis of many commodity and special chemicals. "( [Optimization of succinic acid fermentation with Actinobacillus succinogenes by response surface methodology].
Huang, R; Liao, S; Mi, H; Qin, Y; Shen, N; Wang, Q; Xie, N; Zhu, Q, 2013
)
2.17
"Succinic acid is an important precursor for the synthesis of high-value-added products. "( Construction of reductive pathway in Saccharomyces cerevisiae for effective succinic acid fermentation at low pH value.
Liu, Y; Wang, C; Xing, J; Yan, D; Yang, M; Zhou, J, 2014
)
2.07
"Succinic acid is an important platform chemical that has broad applications and is been listed as one of the top twelve bio-based chemicals produced from biomass by the US Department of Energy. "( Model-assisted formate dehydrogenase-O (fdoH) gene knockout for enhanced succinate production in Escherichia coli from glucose and glycerol carbon sources.
Md Illias, R; Mienda, BS; Shamsir, MS, 2016
)
1.88
"Succinic acid is an important platform chemical with a variety of applications. "( Model-aided atpE gene knockout strategy in Escherichia coli for enhanced succinic acid production from glycerol.
Md Illias, R; Mienda, BS; Shamsir, MS, 2016
)
2.11
"Succinic acid is an important C4-building chemical platform for many applications. "( Enterobacter sp. LU1 as a novel succinic acid producer - co-utilization of glycerol and lactose.
Czernecki, T; Jarocki, P; Kucharska, J; Nowak, A; Podleśny, M; Targoński, Z; Wyrostek, J, 2017
)
2.18
"Succinic acid is a useful chemical and its purification from fermentation broth by ion-exchange resins has widely drawn attention. "( pH neutralization while succinic acid adsorption onto anion-exchange resins.
Li, Q; Li, WL; Liu, BB; Liu, QF; Su, ZG; Tang, H; Wang, D; Xing, JM; Yang, MH, 2010
)
2.11
"Succinic acid is a platform molecule that has recently generated considerable interests. "( Succinic acid production from orange peel and wheat straw by batch fermentations of Fibrobacter succinogenes S85.
Li, Q; Siles, JA; Thompson, IP, 2010
)
3.25
"Succinic acid is a building-block chemical which could be used as the precursor of many industrial products. "( Significance of CO2 donor on the production of succinic acid by Actinobacillus succinogenes ATCC 55618.
Li, HM; Tang, YJ; Zhu, LW; Zou, W, 2011
)
2.07
"Succinic acid is a promising chemical which has a wide range of applications and can be biologically produced. "( Downstream processing of biotechnological produced succinic acid.
Cheng, KK; Liu, DH; Wu, RC; Xu, YZ; Zeng, J; Zhang, JA; Zhao, XB, 2012
)
2.07
"Succinic acid is a highly sought after added-value chemical for which there is no native pre-disposition for production and accmulation in S."( Industrial systems biology of Saccharomyces cerevisiae enables novel succinic acid cell factory.
Cimini, D; Nielsen, J; Olsson, L; Otero, JM; Patil, KR; Poulsen, SG, 2013
)
1.35
"Succinic acid is a four-carbon dicarboxylic acid produced as one of the fermentation products of anaerobic metabolism. "( Genome-based metabolic engineering of Mannheimia succiniciproducens for succinic acid production.
Lee, SJ; Lee, SY; Song, H, 2006
)
2.01
"Succinic acid (SA) is an important platform molecule in the synthesis of a number of commodity and specialty chemicals. "( Effect of different carbon sources on the production of succinic acid using metabolically engineered Escherichia coli.
Andersson, C; Berglund, KA; Hodge, D; Rova, U,
)
1.82
"Succinic acid is an important C4 building block chemical for many applications."( From genome sequence to integrated bioprocess for succinic acid production by Mannheimia succiniciproducens.
Jang, YS; Kim, JM; Kim, TY; Lee, JW; Lee, SY; Song, H, 2008
)
1.32

Effects

Succinic acid (SA) has been recognized as one of the most important bio-based building block chemicals due to its numerous potential applications. It is metabolized by body cells and has a role in the tricarboxylic acid cycle (TCA) as a cycle media component.

ExcerptReferenceRelevance
"Succinic acid (SA) has been produced from rice straw (RS) and sugarcane bagasse (SB) as low-cost feedstocks in this study through sequential peracetic acid (PA) and alkaline peroxide (AP) pretreatment assisted by ultrasound and pre-hydrolysis followed by simultaneous saccharification and fermentation (PSSF). "( Utilizing rice straw and sugarcane bagasse as low-cost feedstocks towards sustainable production of succinic acid.
Hermansyah, H; Perdani, MS; Pratiwi, SF; Putri, DN; Rosarina, D; Sahlan, M; Utami, TS, 2023
)
2.57
"Succinic acid has no adverse effects because it is metabolized by body cells and has a role in the tricarboxylic acid cycle (TCA) as a cycle media component."( A new target for the treatment of endometrium cancer by succinic acid.
Cakmakoglu, B; Catmakas, T; Iplik, ES, 2018
)
1.45
"Succinic acid (SA) has been recognized as one of the most important bio-based building block chemicals due to its numerous potential applications. "( Bioreactors for succinic acid production processes.
Ferone, M; Marzocchella, A; Olivieri, G; Raganati, F, 2019
)
2.3
"Succinic acid (SA) has become a prominent biobased platform chemical with global production quantities increasing annually. "( Continuous and batch cultures of Escherichia coli KJ134 for succinic acid fermentation: metabolic flux distributions and production characteristics.
Nicol, W; van Heerden, CD, 2013
)
2.07
"Succinic acid (SA) has been recognized as one of the most important bio-based building block chemicals due to its numerous potential applications. "( Production of succinic acid by metabolically engineered microorganisms.
Ahn, JH; Jang, YS; Lee, SY, 2016
)
2.24
"Succinic acid has received a great deal of attention as an important green chemical stock for the manufacture of synthetic resins, biodegradable polymers and chemical intermediates. "( [Breeding of monofluoroacetate-resistant strains of Actinobacillus succinogenes and the mechanism based on metabolic flux analysis].
Dong, J; Liu, Y; Ni, Y; Sun, Z; Wei, P; Zheng, P, 2008
)
1.79
"Succinic acid amides have been found to be effective P2-P3 scaffold replacements for peptidic ICE inhibitors. "( Succinic acid amides as P2-P3 replacements for inhibitors of interleukin-1beta converting enzyme (ICE or caspase 1).
Allen, H; Brady, K; Caprathe, B; Galatsis, P; Gilmore, J; Harter, W; Kostlan, C; Linn, K; Lunney, E; Rubin, J; Sheehan, S; Stankovic, C; Talanian, R; Thomas, A, 2010
)
3.25
"Succinic acid has drawn much interest as a precursor of many industrially important chemicals. "( Succinate production from different carbon sources under anaerobic conditions by metabolic engineered Escherichia coli strains.
Bennett, GN; San, KY; Wang, J; Zhu, J, 2011
)
1.81
"Succinic Acid has some positive biological properties."( [Diabetes mellitus in the elderly: succinic acid compounds in treating diabetic neuropathies].
Belikova, TV; Odin, VI; Pushkova, ES, 2002
)
1.31

Actions

ExcerptReferenceRelevance
"The succinic acid prevented the increase of cholesterol, triglyceride and low density lipoproteins in the blood."( Prophylaxis of encephalopathies and risk factors of atherogenesis development in the postresuscitation period in rats by means of succinic acid.
Avruschenko, MS; Gulyaeva, NV; Gurvitch, AM; Lazareva, NA; Mutuskina, EA; Onufriev, MV; Pylova, SI; Stepanichev, MY; Trubina, IE; Volkov, AV; Zarzhetsky, YV, 1997
)
0.98

Treatment

ExcerptReferenceRelevance
"Succinic acid-treated ispaghula husk can be used as an economical hydrophilic matrixing agent."( Modulation of drug release rate of diltiazem-HCl from hydrogel matrices of succinic acid-treated ispaghula husk.
Amin, AF; Chhabaria, MT; Gohel, MC; Lalwani, AN; Panchal, MK, 2000
)
1.26

Toxicity

ExcerptReferenceRelevance
" The oral LD50 was greater than 8 g/kg body weight."( Lack of toxicity/carcinogenicity of monosodium succinate in F344 rats.
Hayashi, Y; Kodama, Y; Maekawa, A; Matsushima, Y; Nagaoka, T; Ogasawara, H; Onodera, H; Shibutani, M; Todate, A, 1990
)
0.28
" The recently released thienamycin antibiotic, imipenem, like the toxic cephalosporins, produces acute proximal tubular necrosis which can be prevented completely by prior administration of probenecid."( Thienamycin nephrotoxicity. Mitochondrial injury and oxidative effects of imipenem in the rabbit kidney.
Fravert, D; Hsu, CY; Tune, BM, 1989
)
0.28
" In vitro toxicity is immediate, nonselective among toxic and nontoxic cephalosporins and reversed by substrate excess."( The mitochondrial respiratory toxicity of cephalosporin antibiotics. An inhibitory effect on substrate uptake.
Hsu, CY; Sibley, RK; Tune, BM, 1988
)
0.27
"Previous studies from our laboratory have demonstrated that the administration of alpha-tocopheryl hemisuccinate (TS), but not unesterified alpha-tocopherol (T), protects hepatocytes from a variety of toxic insults including chemicals, drugs, metals, and oxidative stress."( Role of cellular energy status in tocopheryl hemisuccinate cytoprotection against ethyl methanesulfonate-induced toxicity.
Fariss, MW; Ray, SD, 1994
)
0.29
" Weak acids that are normal cellular metabolites are not toxic in vivo, but weak acids carrying cytotoxic groups offer the potential for selective uptake and toxicity under the conditions of low pHe that exist in many solid tumours."( Selective cellular acidification and toxicity of weak organic acids in an acidic microenvironment.
Dobrowsky, E; Karuri, AR; Tannock, IF, 1993
)
0.29
" Besides its significant antiarrhythmic activity, ethacizin displayed a number of adverse cardiac effects, such as excessive negative inotropic and dromotropic ones."( [Possibilities of correcting adverse effects of anti-arrhythmia agents].
Bartashevich, VV; Galenko-Iaroshevskiĭ, PA; Kanorskiĭ, SG; Khankoeva, AI; Skibitskiĭ, VV; Uvarov, AV, 1996
)
0.29
"25 mM) in the hepatocyte suspensions was rapidly converted to its major conjugate, BPA-glucuronide, and other minor products without marked loss of cell viability, although at a toxic level (0."( Metabolism and cytotoxicity of bisphenol A and other bisphenols in isolated rat hepatocytes.
Nakagawa, Y; Tayama, S, 2000
)
0.31
"Daily treatment of outbred albino mice with gammafos in radioprotective doses of 300 and 500 mg/kg for 4 days produced a cumulative toxic effect."( Effect of melatonin, ascorbic acid, and succinic acid on the cumulative toxic effect of repeated treatment with gammafos (amifostine).
Komarova, SN; Kovtun, VY; Semenova, LA; Ushakov, IB; Vasin, MV, 2004
)
0.59
" This study identified NaDC-1 as a likely and NaDC-3 as a possible molecular target to reduce uptake of this toxic metabolite by the kidney."( Role of Plasma Membrane Dicarboxylate Transporters in the Uptake and Toxicity of Diglycolic Acid, a Metabolite of Diethylene Glycol, in Human Proximal Tubule Cells.
Dwyer, D; Landry, GM; Luttrell-Williams, ES; McMartin, KE; Robinson, CN; Tobin, JD, 2022
)
0.72

Pharmacokinetics

ExcerptReferenceRelevance
" In vivo pharmacokinetic properties and intestinal absorption of PSDS pellets in rat were investigated."( [Intestinal absorption of enteric coating potassium sodium dehydroandroan drographolide succinate pellets in rat and in vivo pharmacokinetics study].
Gao, Y; Huang, GH; Wang, ZL, 2011
)
0.37
" The main drug pharmacokinetic parameters were calculated."( [Intestinal absorption of enteric coating potassium sodium dehydroandroan drographolide succinate pellets in rat and in vivo pharmacokinetics study].
Gao, Y; Huang, GH; Wang, ZL, 2011
)
0.37
" This assay has been successfully applied to a pharmacokinetic and tissue distribution study after intravenous injection of ASE in mouse in a dose of 10 mg/kg."( Preclinical pharmacokinetic analysis of armillarisin succinate ester in mouse plasma and tissues by LC-MS/MS.
Chen, Q; Li, P; Zhang, J; Zhu, J, 2013
)
0.39
" Pharmacokinetic studies on rats showed that the glutarate salt exhibits doubled plasma AUC values in a single dose within an hour compared to the citrate salt."( Salt and cocrystals of sildenafil with dicarboxylic acids: solubility and pharmacokinetic advantage of the glutarate salt.
Desiraju, GR; Ganguly, S; Sanphui, P; Tothadi, S, 2013
)
0.39
" Hence Polymer conjugation utilizing different chemical linkers and polymer compositions was investigated for enhanced pharmacokinetic profile of resveratrol."( Stabilization of resveratrol in blood circulation by conjugation to mPEG and mPEG-PLA polymers: investigation of conjugate linker and polymer composition on stability, metabolism, antioxidant activity and pharmacokinetic profile.
Batty, KT; Benson, HA; Brown, DH; Chen, Y; Siddalingappa, B, 2015
)
0.42
" The in vivo pharmacokinetic study in rats showed that the micelles prolonged the half-life and increased AUC of PTX than Taxol formulation."( In vivo pharmacokinetics, biodistribution and antitumor effect of paclitaxel-loaded micelles based on α-tocopherol succinate-modified chitosan.
Cui, F; Fang, L; Hong, J; Liang, N; Sun, S; Tian, J, 2016
)
0.43

Compound-Compound Interactions

ExcerptReferenceRelevance
" We demonstrate that NV354, in combination with atropine and pralidoxime therapy, significantly improved cerebral mitochondrial complex IV-linked respiration and reduced signs of brain injury in a rodent model of acute DFP exposure."( Succinate prodrugs in combination with atropine and pralidoxime protect cerebral mitochondrial function in a rodent model of acute organophosphate poisoning.
Clayman, CL; Ehinger, JK; Elmér, E; Hansson, MJ; Jang, DH; Janowska, JI; Jose, JS; Karlsson, M; Kilbaugh, TJ; McManus, MJ; Piel, S; Sheldon, M; Starr, J; Ward, JL, 2022
)
0.72

Bioavailability

The study shows the utility of an itraconazole-succinic acid cocrystal. It also demonstrates the potential for CO(2) to replace traditional liquid antisolvents.

ExcerptReferenceRelevance
" The results may be important for elucidating factors affecting iron bioavailability in the small intestine and for the development of foods with improved iron bioavailability."( Organic acids influence iron uptake in the human epithelial cell line Caco-2.
Andlid, T; Salovaara, S; Sandberg, AS, 2002
)
0.31
" The oral bioavailability of drugs in the TMCTs was then evaluated and compared to the simultaneous oral administration of trimebutine maleate-loaded and mosapride citrate-loaded commercial products in the beagle dog."( Development of a novel combination tablet containing trimebutine maleate and mosapride citrate for the treatment of functional dyspepsia.
Cho, KH; Choi, HG; Choi, YK; Kang, JH; Park, YJ; Yong, CS, 2010
)
0.36
" This study shows the utility of an itraconazole-succinic acid cocrystal for improving itraconazole bioavailability while also demonstrating the potential for CO(2) to replace traditional liquid antisolvents in cocrystal preparation, thus making cocrystal production more environmentally benign and scale-up more feasible."( Formation of itraconazole-succinic acid cocrystals by gas antisolvent cocrystallization.
Gupta, RB; Ober, CA, 2012
)
0.93
" Compound 1 displayed suitable in vitro pharmaceutical properties and a favorable in vivo pharmacokinetic profile following intravenous and oral administration, with a calculated bioavailability of 82."( An improved small-molecule inhibitor of FtsZ with superior in vitro potency, drug-like properties, and in vivo efficacy.
Baker, N; Bennett, JM; Berry, J; Collins, I; Czaplewski, LG; Haydon, DJ; Logan, A; Macdonald, R; Macleod, L; Mitchell, JP; Nayal, N; Peasley, H; Srivastava, A; Stokes, NR; Yadav, A, 2013
)
0.39
"This study shows the effect of ion pair formation on intestinal absorption and oral bioavailability of amifostine."( Ion-pair strategy for enabling amifostine oral absorption: rat in situ and in vivo experiments.
Bermejo, M; Foroutan, M; González-Álvarez, I; Mangas-Sanjuan, V; Samiei, N; Shafaati, A; Zarghi, A, 2013
)
0.39
" Moreover, the Cd or Pb uptake in sunflower showed various correlations with pH and some organic acids, which might be due to the fact that the Cd and Pb interfere with the organic acids secretion in rhizosphere of sunflower, and the changes of organic acids altered the form and bioavailability of Cd and Pb in cultures conversely."( Dynamics of three organic acids (malic, acetic and succinic acid) in sunflower exposed to cadmium and lead.
Li, X; Niu, Z; Sun, L; Sun, T, 2013
)
0.64
" Thus, to improve solubility and bioavailability characteristics, cocrystals and salts of the drug have been prepared by treating aliphatic dicarboxylic acids with sildenafil; the N-methylated piperazine of the drug molecule interacts with the carboxyl group of the acid to form a heterosynthon."( Salt and cocrystals of sildenafil with dicarboxylic acids: solubility and pharmacokinetic advantage of the glutarate salt.
Desiraju, GR; Ganguly, S; Sanphui, P; Tothadi, S, 2013
)
0.39
" However, MDG-1 is poorly absorbed and its mechanism of action is still unknown."( Fecal metabonomic study of a polysaccharide, MDG-1 from Ophiopogon japonicus on diabetic mice based on gas chromatography/time-of-flight mass spectrometry (GC TOF/MS).
Cong, W; Feng, Y; Ruan, K; Shen, L; Wang, L; Wang, Y; Wei, H; Wu, F; Zhu, Y, 2014
)
0.4
" Tetracyclines form metal-complexes in natural waters, which could reduce their bioavailability for bacterial uptake."( Organic acids enhance bioavailability of tetracycline in water to Escherichia coli for uptake and expression of antibiotic resistance.
Boyd, SA; Li, H; Teppen, BJ; Tiedje, JM; Zhang, Y, 2014
)
0.4
"The aim of the present work was to design a pH-modified solid dispersion (pH(M)-SD) that can improve the dissolution and bioavailability of poorly water-soluble weakly basic GT0918, a developing anti-prostate cancer drug."( Microenvironmental pH-modified solid dispersions to enhance the dissolution and bioavailability of poorly water-soluble weakly basic GT0918, a developing anti-prostate cancer drug: preparation, characterization and evaluation in vivo.
Fan, Y; Gao, C; Ge, Z; Gong, W; He, S; Huang, X; Shan, L; Tong, Y; Wang, Y; Yang, M, 2014
)
0.4
" The results showed that after the modification by succinic acid, the absorption rate of tea oil tree sawdust for uranium increased significantly by about 20% in 12."( [Absorption of Uranium with Tea Oil Tree Sawdust Modified by Succinic Acid].
Chen, DY; Liu, YS; Peng, Y; Xiong, XY; Zhang, XF, 2015
)
0.91
" Studies in albino rabbits show correspondingly better bioavailability of F1-F3 than Epitol."( The development of carbamazepine-succinic acid cocrystal tablet formulations with improved in vitro and in vivo performance.
Hussain, I; Sun, CC; Ullah, M, 2016
)
0.72
" There is an urgent need to obtain new solid forms of higher solubility to improve the bioavailability of the API (active pharmaceutical ingredient)."( New multi-component solid forms of anti-cancer drug Erlotinib: role of auxiliary interactions in determining a preferred conformation.
Desiraju, GR; Gopi, SP; Rajput, L; Sanphui, P, 2016
)
0.43
"The thermal stability and bioavailability of ASD were higher than that of the non-esterified free AST and common free AST, respectively."( Synthesis, stability and bioavailability of astaxanthin succinate diester.
Qiao, X; Wang, Y; Xu, J; Xue, C; Yang, L; Zhang, T; Zhou, Q, 2018
)
0.48
"05) improvement in bioavailability of CBZ."( RELATIVE BIOAVAILABILITY STUDY OF SUCCINIC ACID COCRYSTAL TABLET AND MARKETED CONVENTIONAL IMMEDIATE RELEASE TABLET FORMULATION OF CARBAMAZEPINE 200 MG IN RABBITS.
Hussain, I; Murtaza, G; Ullah, M, 2016
)
0.71
"Herb borneol is usually used in clinics for the treatment of central nervous system illness, for its ability of blood-brain barrier permeability, although its poor water solubility and poor bioavailability limit its clinical application to some degree."( Conjugation of vitamin E-TPGS and guar gum to carry borneol for enhancing blood-brain barrier permeability.
Cen, Y; Cheng, K; Liu, Y; Rao, L; Zhang, H, 2018
)
0.48
"The objective of this study was to formulate aripiprazole (ARI)-loaded pH-modulated solid dispersions (SD) to enhance solubility, dissolution, and bioavailability via hot-melt extrusion (HME) technology."( Formulation of aripiprazole-loaded pH-modulated solid dispersions via hot-melt extrusion technology: In vitro and in vivo studies.
Bandari, S; Kim, DW; Kolter, K; Langley, N; McFall, H; Murthy, SN; Repka, MA; Sarabu, S; Shankar, V, 2019
)
0.51
" Its low bioavailability justifies the search for more hydrophilic OA derivatives."( Morpholide derivative of the novel oleanolic oxime and succinic acid conjugate diminish the expression and activity of NF-κB and STATs in human hepatocellular carcinoma cells.
Baer-Dubowska, W; Bednarczyk-Cwynar, B; Krajka-Kuźniak, V; Narożna, M; Szaefer, H, 2019
)
0.76
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"Lopinavir (LPV), a well-known drug administered in human immunodeficiency virus (HIV) infection, has shown limitation for pediatric treatment owing to poor aqueous solubility that gives rise to limited oral bioavailability and short plasma half-life (5-6 h)."( Polyethylene glycol (5,000) succinate conjugate of lopinavir and its associated toxicity using Danio rerio as a model organism.
Aremu, OS; Botha, TL; Katata-Seru, L; Mkhize, Z; Wepener, V, 2020
)
0.56
"CoQ10 and Vitamin E are used in medicinal applications, but they are both lipophilic molecules and the poor solubility in aqueous media results in an inefficient administration, poor bioavailability and potential toxicity."( Synthesis and controlled drug delivery studies of a novel Ubiquinol-Polyethylene glycol-Vitamin E adduct.
Cateni, F; Procida, G; Zacchigna, M, 2020
)
0.56
"Solubility and dissolution rate are essential for the oral absorption and bioavailability of poorly soluble drugs."( Combination of co-crystal and nanocrystal techniques to improve the solubility and dissolution rate of poorly soluble drugs.
Bodmeier, R; Huang, Z; Staufenbiel, S, 2022
)
0.72
" breve MCC1274 enhanced the bioavailability of potential anti-oxidative metabolites from the gut and addressed critical gaps in our understanding of the gut-brain axis underlying the mechanisms of the probiotic action of this strain in the improvement of cognitive function."( Bifidobacterium breve MCC1274 Supplementation Increased the Plasma Levels of Metabolites with Potential Anti-Oxidative Activity in APP Knock-In Mice.
Abdelhamid, M; Jung, CG; Michikawa, M; Ohno, K; Zhou, C, 2022
)
0.72
"Our previous studies showed a low oral bioavailability and a predominant distribution of major XLP ingredients in the gut."( Xianglian pill modulates gut microbial production of succinate and induces regulatory T cells to alleviate ulcerative colitis in rats.
Chen, FL; Deng, XH; Hu, YX; Liu, CS; Luo, ZY; Qiu, CW, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
" Dose-response curves for the effect of pentobarbital on respiratory activity of each cell type were constructed with the two substrates."( Differential effect of pentobarbital on chick neurons and astrocytes grown in culture.
Roth-Schechter, BF; Tholey, G, 1982
)
0.26
" In heart fibers a dosage of 100 microg LPS."( Different sensitivity of rabbit heart and skeletal muscle to endotoxin-induced impairment of mitochondrial function.
Gellerich, FN; Neuhof, C; Opalka, JR; Trumbeckaite, S; Zierz, S, 2001
)
0.31
" Urine samples were collected daily for 9 days from both dosed and control animals."( A metabonomic investigation of the biochemical effects of mercuric chloride in the rat using 1H NMR and HPLC-TOF/MS: time dependent changes in the urinary profile of endogenous metabolites as a result of nephrotoxicity.
Bright, J; Knight, R; Lenz, EM; Major, H; Wilson, ID, 2004
)
0.32
" A condition for antidote effect of the Krebs intermediate was sufficiently high dosage (5 mmol/kg), further dose increase made no odds."( Intermediates of Krebs cycle correct the depression of the whole body oxygen consumption and lethal cooling in barbiturate poisoning in rat.
Ivnitsky, JJ; Malakhovsky, VN; Rejniuk, VL; Schäfer, TV, 2004
)
0.32
"Milling is a key process in the preparation of many solid dosage forms."( The effect of crystal morphology and mill type on milling induced crystal disorder.
Chikhalia, V; Forbes, RT; Storey, RA; Ticehurst, M, 2006
)
0.33
"Incorporation of pH modifiers is a commonly used strategy to enhance the dissolution rate of weakly basic drugs from sustained release solid dosage forms."( Microenvironmental pH and microviscosity inside pH-controlled matrix tablets: an EPR imaging study.
Borchert, HH; Gurny, R; Herrmann, W; Kramer, A; Lueckel, B; Ries, A; Siepe, S, 2006
)
0.33
" and tibialis anterior fibers during 35-day gravitational unloading, with the addition of succinate in the diet at a dosage rate of 50 mg per 1 kg animal weight has been investigated."( [Changes in cell respiration of postural muscle fibers under long-term gravitational unloading after dietary succinate supplementation].
Larina, IM; Ogneva, IV; Veselova, OM,
)
0.13
" To compare the effect of once daily bedtime dosing of VECAM 40 and VECAM 20 without food vs OMP 20 mg administered before breakfast on gastric acidity."( The effect of once daily omeprazole and succinic acid (VECAM) vs once daily omeprazole on 24-h intragastric pH.
Atarot, T; Chowers, Y; Fass, R; Pratha, VS, 2012
)
0.65
" Because rotenone, a complex I inhibitor, increases H(2)O(2) production in heart but not in liver mitochondria we investigated the CoQ(2) effect in a dose-response assay of complex I inhibition by rotenone in both mitochondria."( Opposite and tissue-specific effects of coenzyme Q2 on mPTP opening and ROS production between heart and liver mitochondria: role of complex I.
Angoulvant, D; Augeul, L; Couture-Lepetit, E; De Paulis, D; Gharib, A; Gomez, L; Li, B; Ovize, M, 2012
)
0.38
" The dissolution behaviour of the salt in dosage form is compared with two reference commercial products."( Structure and properties of domperidone and its succinate salt.
Berbenni, V; Bini, M; Boiocchi, M; Bruni, G; Capsoni, D; Ferrari, S; Girella, A; Maggi, L; Maietta, M; Marini, A; Milanese, C; Scotti, F, 2013
)
0.39
", CaCO3, CaSO4, BaSO4, SrSO4), showing an average scale inhibition ratio of above 90% at a dosage of 10 mg/L."( Study on polyepoxysuccinic acid reverse osmosis scale inhibitor.
Sun, Y; Wang, Y; Xiang, W, 2009
)
0.69
" In order to probe an alternative dosing design that would preclude this effect, we studied the efficacy of a low dose of the antidepressant imipramine (7 mg/kg/day) delivered via food pellets."( Animal Models of Depression and Drug Delivery with Food as an Effective Dosing Method: Evidences from Studies with Celecoxib and Dicholine Succinate.
Araújo-Correia, M; Cline, BH; Costa-Nunes, JP; Dolgov, O; Kubatiev, A; Markova, N; Steinbusch, HW; Strekalova, T; Valença, A; Yeritsyan, N, 2015
)
0.42
" By the static experiments, effects of reaction time between adsorbent and solvent, dosage of adsorbent, temperature, pH value and initial concentration of uranium were investigated."( [Absorption of Uranium with Tea Oil Tree Sawdust Modified by Succinic Acid].
Chen, DY; Liu, YS; Peng, Y; Xiong, XY; Zhang, XF, 2015
)
0.66
" This necessitates their robust stabilization in order for successful use in a tablet dosage form."( The development of carbamazepine-succinic acid cocrystal tablet formulations with improved in vitro and in vivo performance.
Hussain, I; Sun, CC; Ullah, M, 2016
)
0.72
" The urine of rats dosed with a subcutaneous bolus dose of 20mg 4-MMC/kg was analysed by LC/MS."( Metabolic profile of mephedrone: Identification of nor-mephedrone conjugates with dicarboxylic acids as a new type of xenobiotic phase II metabolites.
Balíková, M; Himl, M; Lhotková, E; Linhart, I; Páleníček, T; Židková, M, 2016
)
0.43
" To evaluate the suitability of the novel excipient focused to develop oral dosage forms, albendazole, a BSC class II compound, was chosen as a model drug."( Promising applications in drug delivery systems of a novel β-cyclodextrin derivative obtained by green synthesis.
García, A; Lamas, MC; Leonardi, D, 2016
)
0.43
" Following a single intravitreal injection, the proposed TA-SA-Glu hydrogel hardly caused apparent retinal toxicity at a dosage of 69 nmol per eye."( Glycosylation-enhanced biocompatibility of the supramolecular hydrogel of an anti-inflammatory drug for topical suppression of inflammation.
Lei, L; Li, X; Song, Q; Xiong, T; Zhang, R; Zhou, Y, 2018
)
0.48
" Among these two antibiotics, colistin is considered toxic, and therefore, its clinical use and dosage need cautious approach."( Use of succinic & oxalic acid in reducing the dosage of colistin against New Delhi metallo-β-lactamase-1 bacteria.
Chandar, B; Kumar, R; Parani, M, 2018
)
0.48
" Supplementation the enzymatic process with 10% dosage of endoxylanases (Cellic® HTec2) reduced the hydrolysis time required to achieve the maximum glucan conversion by 44-46% and increased the xylose yield by 10% compared to the process with Cellic® CTec2."( Integrated production of cellulosic bioethanol and succinic acid from rapeseed straw after dilute-acid pretreatment.
Alvarado-Morales, M; Angelidaki, I; Dąbkowska, K; Kuglarz, M, 2018
)
0.73
" Using the Box-Behnken design (BBD) approach, operating parameters such as reaction time, microwave power, and catalyst dosing were optimized for SA esterification with MeOH."( Optimization of microwave-assisted esterification of succinic acid using Box-Behnken design approach.
Chakraborty, M; Parikh, PA; Umrigar, V, 2023
)
1.16
" The sorption data at the optimized operating conditions (pH 2, sorbent dosage 3 mg, time 18 min) showed the highest sorption capacity of 40 mg/g."( Biomimetic Electrochemical Sensors Based on Core-Shell Imprinted Polymers for Targeted Sunset Yellow Estimation in Environmental Samples.
Ali, N; Khan, A; Khan, H; Khan, S; Malik, S; Rahman, G; Sotomayor, MDPT, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (89 Product(s))

Product Categories

Product CategoryProducts
Other53
Sweeteners, Syrups, Simple syrups1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Matières grasses, Matières grasses végétales, Produits de l'olivier, Huiles, Huiles d'olive, Huiles d'olive vierges extra, Huiles d'olive vierges1
Snacks, Sweet snacks, Biscuits and cakes, Cakes, Cooking helpers, Pastry helpers, Baking Mixes, Dessert mixes, Cake mixes1
Frozen foods1
Petit-déjeuners, Produits à tartiner, Produits à tartiner sucrés, Produits de la ruche, Produits d'élevages, Édulcorants, Miels, Miels de fleurs1
Breakfasts, Spreads, Sweet spreads, Bee products, Farming products, Sweeteners, Honeys, Forest honeys1
Dairies, Fermented foods, Fermented milk products, Cheeses2
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Fruits à coques et dérivés, Fruits à coques, Noix de cajou1
en:sea-salts1
Boissons, Sirops, Sirops aromatisés, Sirops de grenadine1
Milchprodukte, Fermentierte Lebensmittel, Fermentierte Milch, Käse1
Lanches comida,Lanches doces,Biscoitos e Bolos,Biscoitos,en:Almond cookies1
Plats préparés, Quenelles, Quenelles nature1
Condiments, Sauces, Mayonnaises, en:egg-free-mayonnaises1
Productos del mar, Molusco, Calamares1
Cooked chicken1
Pflanzliche Lebensmittel und Getränke,Pflanzliche Lebensmittel,Getreide und Kartoffeln,Getreideprodukte,Mehle,Getreidemehle,Weizenmehle,Dinkelmehle,Dinkelmehle Type 10501
Milchprodukte, Fermentierte Lebensmittel, Fermentierte Milch, Brotaufstriche, Käse, Gesalzene Aufstriche, Streichkäse1
Beverages,Alcoholic beverages,Carbonated drinks,Horoyoi1
Produits laitiers, Matières grasses, Produits à tartiner, Matières grasses à tartiner, Matières grasses animales, Matière grasse laitière, Produits laitiers à tartiner, Beurres1
Boissons, Boissons alcoolisées, Bières, Bières blanches1
Snacks, Sweet snacks, Cocoa and its products, Chocolates, Milk chocolates, Milk chocolate bar1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Céréales et pommes de terre, Céréales et dérivés1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Petit-déjeuners, Produits à tartiner, Pâtes à tartiner végétales, Produits à tartiner sucrés1
Plant-based foods and beverages, Plant-based foods, Condiments, Spices, Peppers, Black peppers1
Imbiss, Süßer Snack, Kakao und Kakaoprodukte, Schokoladen, Bitterschokoladen1
Aliments et boissons à base de végétaux, Boissons, Aliments d'origine végétale, Céréales et pommes de terre, Substituts de produits laitiers, Céréales et dérivés, Substituts du lait, Boissons à base de végétaux, Boissons végétales, Boissons végétales de c1
Pies1
Żywność i napoje na bazie roślin, Napoje, Napoje na bazie roślin, Napoje owocowe, Soki i nektary, Soki owocowe, Soki pomarańczowe1
Imbiss, Süßer Snack, Kekse und Kuchen, Kekse, en:Kekse, en:Kekse und Kuchen, en:Mürbeteigkekse, en:Süßer Snack1
Professional Supplements1
Weight Management1
Vitamins & Supplements1
Beauty & Personal Care1
Herbs, Botanicals & Homeopathy1

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
All-in-one super syrupSweeteners, Syrups, Simple syrupssodium benzoate,ethyl vanillin,propylene glycol2024-02-12
complete pancake & waffle mixSnacks, Sweet snacks, Biscuits and cakes, Cakes, Cooking helpers, Pastry helpers, Baking Mixes, Dessert mixes, Cake mixesniacin,riboflavin2024-02-12
e quate sleep aidOtherpropylene glycol,titanium dioxide2024-02-13
8 Mexican Fajita Cooked Chicken Fillet SkewersFarmfoodsCooked chickenXylose2024-08-02
Designs for Sport Mito NRG Complex - NSF Certified for Sport -- 120 Vegetarian CapsulesDesigns for SportProfessional SupplementsCoenzyme Q10, Creatine, L-Carnitine, Malic Acid, Manganese, Niacin, Pantethine, Vitamin B6, Trans-Resveratrol, Riboflavin, D-Ribose, Succinic Acid, Thiamin, Alpha-Lipoic Acid, Vitamin B12, Vitamin B62024-11-29 10:47:42
Natural Balance Water-X™ Herbal Blend Maximum Strength -- 60 Vegetarian CapsulesNatural BalanceWeight ManagementKelp, cellulose, Fumarate, maltodextrin, Succinic Acid2024-11-29 10:47:42
Source Naturals Allercetin Allergy and Sinus -- 48 TabletsSource NaturalsVitamins & Supplementshistamine hydrochloride, potassium iodide, succinic acid2024-11-29 10:47:42
Tree to Tub Anti-Aging Retinol Body Lotion -- 8.5 fl ozTree to TubBeauty & Personal Carecaprylyl glycol, orange, cetearyl alcohol, palm, tocopherol, ethyl ferulate, tocopherol, vitamin E, glycerin, phenoxyethanol, propanediol, retinol, sodium benzoate, sodium hydroxide, succinic acid, urea2024-11-29 10:47:42
Zahler ParaGuard™ Parasite Cleanse & Detox Intestinal Flora Support -- 90 SoftgelsZahlerHerbs, Botanicals & Homeopathyglycerin, Wormwood2024-11-29 10:47:42

Roles (5)

RoleDescription
nutraceuticalA product in capsule, tablet or liquid form that provide essential nutrients, such as a vitamin, an essential mineral, a protein, an herb, or similar nutritional substance.
radiation protective agentAny compound that is able to protect normal cells from the damage caused by radiation therapy.
anti-ulcer drugOne of various classes of drugs with different action mechanisms used to treat or ameliorate peptic ulcer or irritation of the gastrointestinal tract.
micronutrientAny nutrient required in small quantities by organisms throughout their life in order to orchestrate a range of physiological functions.
fundamental metaboliteAny metabolite produced by all living cells.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
alpha,omega-dicarboxylic acid
C4-dicarboxylic acidAny dicarboxylic acid that contains four carbon atoms.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (147)

PathwayProteinsCompounds
Cellular response to hypoxia624
Oxygen-dependent asparagine hydroxylation of Hypoxia-inducible Factor Alpha14
Citric Acid Cycle2127
Arginine and Proline Metabolism2047
Glutamate Metabolism2244
Ketone Body Metabolism413
Valine, Leucine, and Isoleucine Degradation2852
Oxidation of Branched-Chain Fatty Acids1122
Mitochondrial Electron Transport Chain2016
Butyrate Metabolism718
Carnitine Synthesis517
Phytanic Acid Peroxisomal Oxidation620
beta-Ketothiolase Deficiency2852
2-Methyl-3-hydroxybutyryl-CoA Dehydrogenase Deficiency2852
Propionic Acidemia2852
3-Hydroxy-3-methylglutaryl-CoA Lyase Deficiency2852
Maple Syrup Urine Disease2852
3-Methylcrotonyl-CoA Carboxylase Deficiency Type I2852
3-Methylglutaconic Aciduria Type I2852
3-Methylglutaconic Aciduria Type III2852
Methylmalonate Semialdehyde Dehydrogenase Deficiency2852
Methylmalonic Aciduria2852
4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency2244
Homocarnosinosis2244
Hyperinsulinism-Hyperammonemia Syndrome2244
Prolidase Deficiency (PD)2047
Arginine: Glycine Amidinotransferase Deficiency (AGAT Deficiency)2047
Hyperprolinemia Type II2047
Hyperprolinemia Type I2047
Prolinemia Type II2047
Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency)2047
Ornithine Aminotransferase Deficiency (OAT Deficiency)2047
Isovaleric Aciduria2852
Refsum Disease620
2-Hydroxyglutric Aciduria (D and L Form)2244
3-Methylglutaconic Aciduria Type IV2852
Creatine Deficiency, Guanidinoacetate Methyltransferase Deficiency2047
Hyperornithinemia with Gyrate Atrophy (HOGA)2047
Hyperornithinemia-Hyperammonemia-Homocitrullinuria [HHH-syndrome]2047
L-Arginine:Glycine Amidinotransferase Deficiency2047
3-Hydroxyisobutyric Acid Dehydrogenase Deficiency2852
3-Hydroxyisobutyric Aciduria2852
Isobutyryl-CoA Dehydrogenase Deficiency2852
Isovaleric Acidemia2852
Congenital Lactic Acidosis2127
Fumarase Deficiency2127
Mitochondrial Complex II Deficiency2127
2-Ketoglutarate Dehydrogenase Complex Deficiency2127
Pyruvate Dehydrogenase Deficiency (E3)2127
Pyruvate Dehydrogenase Deficiency (E2)2127
Succinic Semialdehyde Dehydrogenase Deficiency2244
Succinyl CoA: 3-Ketoacid CoA Transferase Deficiency413
Warburg Effect4652
Lysine Biosynthesis1924
Taurine Metabolism412
TCA Cycle1825
Inner Membrane Transport7862
L-Glutamate Metabolism2420
Arginine Metabolism2848
Ornithine Metabolism1631
Methionine Biosynthesis1018
Gluconeogenesis from L-Malic Acid2024
Oxidative Phosphorylation269
Sulfur Metabolism2833
Sulfur Metabolism (Butanesulfonate)2834
Sulfur Metabolism (Propanesulfonate)2834
Sulfur Metabolism (Ethanesulfonate)2834
Sulfur Metabolism (Isethionate)2834
Sulfur Metabolism (Methanesulfonate)2834
Secondary Metabolites: Glyoxylate Cycle715
TCA cycle (ubiquinol-2)1824
TCA cycle (ubiquinol-3)1823
TCA cycle (ubiquinol-4)1824
TCA cycle (ubiquinol-5)1823
TCA cycle (ubiquinol-6)1825
TCA cycle (ubiquinol-7)1825
TCA cycle (ubiquinol-8)1825
TCA cycle (ubiquinol-9)1823
TCA cycle (ubiquinol-10)1824
Taurine Metabolism I412
2-Oxopent-4-enoate Metabolism1725
Glycolate and Glyoxylate Degradation II1221
TCA cycle (ubiquinol-0)1825
2-Oxopent-4-enoate Metabolism 21725
Propanoyl-CoA Degradation312
Conversion of Succinate to Propanoate37
4-Aminobutanoate Degradation I39
The Oncogenic Action of 2-Hydroxyglutarate2734
The Oncogenic Action of Succinate2933
The Oncogenic Action of Fumarate2934
Glutaminolysis and Cancer3536
4-Aminobutanoate Degradation29
Glyoxylate Cycle613
The Oncogenic Action of L-2-Hydroxyglutarate in Hydroxyglutaric aciduria2835
The Oncogenic Action of D-2-Hydroxyglutarate in Hydroxyglutaric aciduria2936
Selenocompound Metabolism923
Glutamic Acid Metabolism1317
Flavonoid Biosynthesis1150
Leucopelargonidin and Leucocyanidin Biosynthesis314
Flavone and Flavonol Biosynthesis627
Gibberellin Biosynthesis I (Early C-3 Hydroxylation)313
Gibberellin Biosynthesis II (Early C-13 Hydroxylation)314
Gibberellin Biosynthesis III (Non C-3, Non C-13 Hydroxylation)314
Butanoate Metabolism922
2-Methyl-3-hydroxybutryl-CoA Dehydrogenase Deficiency2952
Succinic acid + Ubiquinone = Fumaric acid + Ubiquinol ( Tyrosine metabolism )24
Arginine and Proline metabolism ( Arginine and Proline metabolism )4255
Butanoate metabolism ( Butanoate metabolism )1518
Succinyl-CoA + Acetoacetic acid = Succinic acid + Acetoacetyl-CoA ( Valine,Leucine and Isoleucine degradation )14
Citrate cycle ( Citrate cycle )2129
CoA + GTP + Succinic acid = Succinyl-CoA + GDP + Orthophosphate ( Citrate cycle )26
CoA + ATP + Succinic acid = Succinyl-CoA + ADP + Orthophosphate ( Citrate cycle )16
Glutamic acid and Glutamine metabolism ( Glutamic acid and Glutamine metabolism )1926
NAD+ + Succinate semialdehyde + H2O = NADH + Succinic acid ( Glutamic acid and Glutamine metabolism )15
Lysine degradation ( Lysine degradation )2029
Valine,Leucine and Isoleucine degradation ( Valine,Leucine and Isoleucine degradation )2936
Amino acid metabolism pathway excerpt: histidine catabolism extension016
Succinate Signalling67
Succinate Signalling During Inflammation137
Citrate Cycle1930
TCA Cycle (Ubiquinol-2)424
TCA Cycle (Ubiquinol-3)423
TCA Cycle (Ubiquinol-4)424
TCA Cycle (Ubiquinol-5)423
TCA Cycle (Ubiquinol-6)425
TCA Cycle (Ubiquinol-7)425
TCA Cycle (Ubiquinol-8)425
TCA Cycle (Ubiquinol-9)423
TCA Cycle (Ubiquinol-10)424
TCA Cycle (Ubiquinol-0)425
TCA cycle (plant)121
TCA cycle variation I719
aerobic respiration -- electron donors reaction list314
aerobic respiration -- electron donor III29
TCA cycle variation II618
(5R)-carbapenem biosynthesis25
methionine and methyl-donor-molecule biosynthesis95
TCA cycle variation IV169
aerobic respiration (cyanide insensitive, alternative oxidase) -- electron donors06
aromatic compound degradation08
TCA cycle, aerobic respiration020
GABA degradation09
aerobic respiration (cyanide sensitive) -- electron donors06
Central carbon metabolism019
TCA cycle010
Electron transport chain010
Principal pathways of carbon metabolism07
Primary carbon metabolism2330
Krebs cycle110
TCA cycle (Krebs cycle)3019
AtMetExpress overview0109
Alanine and aspartate metabolism015
Electron transport chain: OXPHOS system in mitochondria010
TCA cycle and deficiency of pyruvate dehydrogenase complex (PDHc)015
Metabolism overview078
Biochemical pathways: part I0466
Amino acid metabolism094
TCA cycle (aka Krebs or citric acid cycle)024

Protein Targets (21)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.02510.003245.467312,589.2998AID2517
acetylcholinesteraseHomo sapiens (human)Potency0.77620.002541.796015,848.9004AID1347398
RAR-related orphan receptor gammaMus musculus (house mouse)Potency6.30000.006038.004119,952.5996AID1159521
TDP1 proteinHomo sapiens (human)Potency33.49830.000811.382244.6684AID686979
GLI family zinc finger 3Homo sapiens (human)Potency31.57490.000714.592883.7951AID1259369
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency8.70900.01237.983543.2770AID1645841
farnesoid X nuclear receptorHomo sapiens (human)Potency61.64480.375827.485161.6524AID743220
estrogen nuclear receptor alphaHomo sapiens (human)Potency55.22520.000229.305416,493.5996AID743079; AID743080
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency71.30460.023723.228263.5986AID743223
lamin isoform A-delta10Homo sapiens (human)Potency0.31620.891312.067628.1838AID1487
Cellular tumor antigen p53Homo sapiens (human)Potency1.41040.002319.595674.0614AID651631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Lysine-specific demethylase 4EHomo sapiens (human)IC50 (µMol)710.00000.20001.95696.3096AID1798635
Prolyl 4-hydroxylaseParamecium bursaria Chlorella virus 1IC50 (µMol)1,000.00005.00006.26678.5000AID1543452
Solute carrier family 13 member 3Homo sapiens (human)IC50 (µMol)107.0000107.0000107.0000107.0000AID1794820
Egl nine homolog 1Homo sapiens (human)IC50 (µMol)3,362.76670.00701.86148.0000AID344926; AID446353; AID721521
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Protein (aspartate Aminotransferase)Escherichia coliKd2,400.00001,500.00001,950.00002,400.0000AID977611
Chain A, Aspartate AminotransferaseEscherichia coliKd2,400.00001,500.00001,950.00002,400.0000AID977611
Egl nine homolog 1Homo sapiens (human)Kd100.00000.42001.95863.4000AID446352; AID446356
Methyl-accepting chemotaxis protein NahYPseudomonas putidaKd82.00008.50008.50008.5000AID1799787
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (157)

Processvia Protein(s)Taxonomy
regulation of gene expressionLysine-specific demethylase 4EHomo sapiens (human)
chromatin remodelingLysine-specific demethylase 4EHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
heme biosynthetic processDelta-aminolevulinic acid dehydrataseEscherichia coli K-12
protoporphyrinogen IX biosynthetic processDelta-aminolevulinic acid dehydrataseEscherichia coli K-12
heme biosynthetic processDelta-aminolevulinic acid dehydrataseEscherichia coli K-12
tetrapyrrole biosynthetic processDelta-aminolevulinic acid dehydrataseEscherichia coli K-12
proteolysisN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
protein deglycosylationN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
pyruvate metabolic processNADP-dependent malic enzyme, mitochondrialHomo sapiens (human)
malate metabolic processNADP-dependent malic enzyme, mitochondrialHomo sapiens (human)
aerobic respirationNADP-dependent malic enzyme, mitochondrialHomo sapiens (human)
oxygen metabolic processNADP-dependent malic enzyme, mitochondrialHomo sapiens (human)
dicarboxylic acid transportSolute carrier family 13 member 3Homo sapiens (human)
lipid transportSolute carrier family 13 member 3Homo sapiens (human)
alpha-ketoglutarate transportSolute carrier family 13 member 3Homo sapiens (human)
citrate transportSolute carrier family 13 member 3Homo sapiens (human)
glutathione transmembrane transportSolute carrier family 13 member 3Homo sapiens (human)
sodium ion transmembrane transportSolute carrier family 13 member 3Homo sapiens (human)
succinate transmembrane transportSolute carrier family 13 member 3Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 13 member 3Homo sapiens (human)
response to hypoxiaEgl nine homolog 1Homo sapiens (human)
intracellular iron ion homeostasisEgl nine homolog 1Homo sapiens (human)
intracellular oxygen homeostasisEgl nine homolog 1Homo sapiens (human)
negative regulation of DNA-binding transcription factor activityEgl nine homolog 1Homo sapiens (human)
regulation of angiogenesisEgl nine homolog 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIEgl nine homolog 1Homo sapiens (human)
negative regulation of cyclic-nucleotide phosphodiesterase activityEgl nine homolog 1Homo sapiens (human)
cardiac muscle tissue morphogenesisEgl nine homolog 1Homo sapiens (human)
heart trabecula formationEgl nine homolog 1Homo sapiens (human)
ventricular septum morphogenesisEgl nine homolog 1Homo sapiens (human)
labyrinthine layer developmentEgl nine homolog 1Homo sapiens (human)
response to nitric oxideEgl nine homolog 1Homo sapiens (human)
regulation of modification of postsynaptic structureEgl nine homolog 1Homo sapiens (human)
regulation protein catabolic process at postsynapseEgl nine homolog 1Homo sapiens (human)
peptidyl-proline hydroxylation to 4-hydroxy-L-prolineEgl nine homolog 1Homo sapiens (human)
cellular response to hypoxiaEgl nine homolog 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (60)

Processvia Protein(s)Taxonomy
metal ion bindingLysine-specific demethylase 4EHomo sapiens (human)
histone H3K9me2/H3K9me3 demethylase activityLysine-specific demethylase 4EHomo sapiens (human)
histone H3K9 demethylase activityLysine-specific demethylase 4EHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
magnesium ion bindingDelta-aminolevulinic acid dehydrataseEscherichia coli K-12
porphobilinogen synthase activityDelta-aminolevulinic acid dehydrataseEscherichia coli K-12
zinc ion bindingDelta-aminolevulinic acid dehydrataseEscherichia coli K-12
lyase activityDelta-aminolevulinic acid dehydrataseEscherichia coli K-12
metal ion bindingDelta-aminolevulinic acid dehydrataseEscherichia coli K-12
N4-(beta-N-acetylglucosaminyl)-L-asparaginase activityN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
protein bindingN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
peptidase activityN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
malic enzyme activityNADP-dependent malic enzyme, mitochondrialHomo sapiens (human)
malate dehydrogenase (decarboxylating) (NADP+) activityNADP-dependent malic enzyme, mitochondrialHomo sapiens (human)
oxaloacetate decarboxylase activityNADP-dependent malic enzyme, mitochondrialHomo sapiens (human)
metal ion bindingNADP-dependent malic enzyme, mitochondrialHomo sapiens (human)
NAD bindingNADP-dependent malic enzyme, mitochondrialHomo sapiens (human)
NADP+ bindingNADP-dependent malic enzyme, mitochondrialHomo sapiens (human)
dicarboxylic acid transmembrane transporter activitySolute carrier family 13 member 3Homo sapiens (human)
protein bindingSolute carrier family 13 member 3Homo sapiens (human)
citrate transmembrane transporter activitySolute carrier family 13 member 3Homo sapiens (human)
alpha-ketoglutarate transmembrane transporter activitySolute carrier family 13 member 3Homo sapiens (human)
succinate transmembrane transporter activitySolute carrier family 13 member 3Homo sapiens (human)
high-affinity sodium:dicarboxylate symporter activitySolute carrier family 13 member 3Homo sapiens (human)
sodium:dicarboxylate symporter activitySolute carrier family 13 member 3Homo sapiens (human)
glutathione transmembrane transporter activitySolute carrier family 13 member 3Homo sapiens (human)
protein bindingEgl nine homolog 1Homo sapiens (human)
ferrous iron bindingEgl nine homolog 1Homo sapiens (human)
2-oxoglutarate-dependent dioxygenase activityEgl nine homolog 1Homo sapiens (human)
enzyme bindingEgl nine homolog 1Homo sapiens (human)
L-ascorbic acid bindingEgl nine homolog 1Homo sapiens (human)
peptidyl-proline dioxygenase activityEgl nine homolog 1Homo sapiens (human)
hypoxia-inducible factor-proline dioxygenase activityEgl nine homolog 1Homo sapiens (human)
peptidyl-proline 4-dioxygenase activityEgl nine homolog 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (29)

Processvia Protein(s)Taxonomy
nucleusLysine-specific demethylase 4EHomo sapiens (human)
nucleoplasmLysine-specific demethylase 4EHomo sapiens (human)
chromatinLysine-specific demethylase 4EHomo sapiens (human)
nucleusLysine-specific demethylase 4EHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
cytosolDelta-aminolevulinic acid dehydrataseEscherichia coli K-12
cytosolDelta-aminolevulinic acid dehydrataseEscherichia coli K-12
extracellular regionN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
extracellular spaceN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
lysosomeN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
endoplasmic reticulumN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
azurophil granule lumenN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
cytoplasmN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
lysosomeN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
mitochondrionNADP-dependent malic enzyme, mitochondrialHomo sapiens (human)
mitochondrial matrixNADP-dependent malic enzyme, mitochondrialHomo sapiens (human)
mitochondrionNADP-dependent malic enzyme, mitochondrialHomo sapiens (human)
plasma membraneSolute carrier family 13 member 3Homo sapiens (human)
basolateral plasma membraneSolute carrier family 13 member 3Homo sapiens (human)
extracellular exosomeSolute carrier family 13 member 3Homo sapiens (human)
plasma membraneSolute carrier family 13 member 3Homo sapiens (human)
cytoplasmEgl nine homolog 1Homo sapiens (human)
cytosolEgl nine homolog 1Homo sapiens (human)
postsynaptic densityEgl nine homolog 1Homo sapiens (human)
intracellular membrane-bounded organelleEgl nine homolog 1Homo sapiens (human)
glutamatergic synapseEgl nine homolog 1Homo sapiens (human)
nucleusEgl nine homolog 1Homo sapiens (human)
cytoplasmEgl nine homolog 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (74)

Assay IDTitleYearJournalArticle
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID349747Inhibition of human recombinant PHD2 (181-426) expressed in Escherichia coli BL21 (DE3) by TR-FRET assay2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Application of a proteolysis/mass spectrometry method for investigating the effects of inhibitors on hydroxylase structure.
AID1543452Inhibition of N-terminal His6-tagged recombinant Paramecium bursaria chlorella virus 1 CPH expressed in Escherichia coli Rosetta 2 (DE3) cells pre-incubated for 5 mins before 2OG as substrate and Fe2 as co-factor addition in presence of L-ascorbate and me2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Inhibition of a viral prolyl hydroxylase.
AID110255Antileukemic activity of compound against the P-388 lymphocytic leukemic BDF1 male mice at 0.6(mg/kg)/day, administered intraperitoneally; 10.7/9.66 (Treated/control)1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Antitumor agents. 44. Bis(helenalinyl) esters and related derivatives as novel potent antileukemic agents.
AID721521Inhibition of PHD2 (unknown origin)2013Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2
Reporter ligand NMR screening method for 2-oxoglutarate oxygenase inhibitors.
AID344917Inhibition of 2-oxoglutarate-dependent human JMJD2E in presence of excess H3K9me3 peptide and 10 uM Fe2 by FDH coupled assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases.
AID344926Inhibition of 2-oxoglutarate-dependent human recombinant HIF PHD2 preincubated for 1 hr2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases.
AID721528Displacement of 2OG from FIH (unknown origin) expressed in Escherichia coli at 400 uM2013Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2
Reporter ligand NMR screening method for 2-oxoglutarate oxygenase inhibitors.
AID398684Toxicity in brine shrimp1995Journal of natural products, Aug, Volume: 58, Issue:8
Identification of 3-hydroxy-3-methylglutaric acid (HMG) as a hypoglycemic principle of Spanish moss (Tillandsia usneoides).
AID446353Inhibition of human PHD2 at 293K temperature by solvent relaxation technique2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Using NMR solvent water relaxation to investigate metalloenzyme-ligand binding interactions.
AID344918Inhibition of 2-oxoglutarate-dependent human JMJD2E preincubated for 30 mins by FDH coupled assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases.
AID1136878Antiyeast activity against Candida albicans clinical isolate 1-V assessed as total inhibition of fungal growth after 24 to 48 hrs by microdilution-colorimetric method1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Anticandidal activity of 5-fluorocytosine-peptide conjugates.
AID446352Binding affinity to human PHD2 by nondenaturing ESI-MS2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Using NMR solvent water relaxation to investigate metalloenzyme-ligand binding interactions.
AID19262Aqueous solubility2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Prediction of drug solubility from Monte Carlo simulations.
AID344916Inhibition of 2-oxoglutarate-dependent human JMJD2E in presence of excess 2-oxoglutarate and 10 uM Fe2 by FDH coupled assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases.
AID681141TP_TRANSPORTER: uptake in Xenopus laevis oocytes2001Molecular pharmacology, May, Volume: 59, Issue:5
Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.
AID447578Inhibition of HDAC in human Hela cells nuclear extracts assessed as residual activity at 500 uM by fluorimetric assay2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
Molecular modifications on carboxylic acid derivatives as potent histone deacetylase inhibitors: Activity and docking studies.
AID1136877Antiyeast activity against Saccharomyces cerevisiae 9763 assessed as total inhibition of fungal growth after 24 to 48 hrs by microdilution-colorimetric method1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Anticandidal activity of 5-fluorocytosine-peptide conjugates.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1763191Inhibition of TET (unknown origin)2021Bioorganic & medicinal chemistry, 06-01, Volume: 39SAR insights into TET2 catalytic domain inhibition: Synthesis of 2-Hydroxy-4-Methylene-pentanedicarboxylates.
AID258399Inhibition of p53-HDM2 interaction at 50 ug/ml2006Bioorganic & medicinal chemistry letters, Jan-01, Volume: 16, Issue:1
Hexylitaconic acid: a new inhibitor of p53-HDM2 interaction isolated from a marine-derived fungus, Arthrinium sp.
AID328866Binding affinity to Pyrococcus horikoshii sodium-coupled aspartate transporter2007Nature, Jan-25, Volume: 445, Issue:7126
Coupling substrate and ion binding to extracellular gate of a sodium-dependent aspartate transporter.
AID121647In vivo antileukemic activity against P-388 lymphocytic leukemia in BDF1 male mice at 60 mg/kg/day intraperitoneal dose expressed as T/C1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Antitumor agents. 44. Bis(helenalinyl) esters and related derivatives as novel potent antileukemic agents.
AID95754Protein interaction energy by using binding affinity towards human L-xylulose reductase enzyme2003Bioorganic & medicinal chemistry letters, Apr-17, Volume: 13, Issue:8
Structure-based design of inhibitors of human L-xylulose reductase modelled into the active site of the enzyme.
AID1136880Antiyeast activity against Candida krusei 1-T assessed as total inhibition of fungal growth after 24 to 48 hrs by microdilution-colorimetric method1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Anticandidal activity of 5-fluorocytosine-peptide conjugates.
AID446356Binding affinity to human PHD2-Mn(II) using 12.5% H2O/87.5% D2O MQC spectrometer operated at 500 MHz at 298K temperature2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Using NMR solvent water relaxation to investigate metalloenzyme-ligand binding interactions.
AID349748Destabilizing effect on human recombinant PHD2 (181-426) expressed in Escherichia coli BL21 (DE3) assessed as half life by limited trypsinolysis/MALDI-MS analysis in presence of ferrous ion2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Application of a proteolysis/mass spectrometry method for investigating the effects of inhibitors on hydroxylase structure.
AID216185Anti-Herpes simplex virus type-1 activity in vero cells using plaque inhibition assay1999Journal of medicinal chemistry, Aug-26, Volume: 42, Issue:17
Virtual combinatorial syntheses and computational screening of new potential anti-herpes compounds.
AID721529Displacement of 2OG from catalytic domain of PHD2 (181 to 426) (unknown origin) expressed in Escherichia coli at 400 uM2013Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2
Reporter ligand NMR screening method for 2-oxoglutarate oxygenase inhibitors.
AID429168Activation of human recombinant wild type mitochondrial NADP-ME expressed in Escherichia coli BL21 assessed as one-half maximal activation by spectrophotometry2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Effects of structural analogues of the substrate and allosteric regulator of the human mitochondrial NAD(P)+-dependent malic enzyme.
AID1136879Antiyeast activity against Candida albicans WD 18-4 assessed as total inhibition of fungal growth after 24 to 48 hrs by microdilution-colorimetric method1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Anticandidal activity of 5-fluorocytosine-peptide conjugates.
AID398683Hypoglycemic activity in Swiss-Webster mouse assessed as change plasma glucose level at 250 mg/kg, ip after 4 hrs1995Journal of natural products, Aug, Volume: 58, Issue:8
Identification of 3-hydroxy-3-methylglutaric acid (HMG) as a hypoglycemic principle of Spanish moss (Tillandsia usneoides).
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2013Archives of biochemistry and biophysics, Oct-01, Volume: 538, Issue:1
Structural basis of substrate selectivity of Δ(1)-pyrroline-5-carboxylate dehydrogenase (ALDH4A1): semialdehyde chain length.
AID1345450Human succinate receptor (Succinate receptor)2013Journal of biomolecular screening, Jun, Volume: 18, Issue:5
Screening β-arrestin recruitment for the identification of natural ligands for orphan G-protein-coupled receptors.
AID1345450Human succinate receptor (Succinate receptor)2004Nature, May-13, Volume: 429, Issue:6988
Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2000Journal of biochemistry, Feb, Volume: 127, Issue:2
Cocrystallization of a mutant aspartate aminotransferase with a C5-dicarboxylic substrate analog: structural comparison with the enzyme-C4-dicarboxylic analog complex.
AID1811Experimentally measured binding affinity data derived from PDB2000Journal of biochemistry, Feb, Volume: 127, Issue:2
Cocrystallization of a mutant aspartate aminotransferase with a C5-dicarboxylic substrate analog: structural comparison with the enzyme-C4-dicarboxylic analog complex.
AID1798635FDH Coupled Inhibition Assay from Article 10.1021/jm800936s: \\Inhibitor Scaffolds for 2-Oxoglutarate-Dependent Histone Lysine Demethylases.\\2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases.
AID1799605PBGS Assay from Article 10.1002/1439-7633(20010504)2: \\Inhibition studies of porphobilinogen synthase from Escherichia coli differentiating between the two recognition sites.\\2001Chembiochem : a European journal of chemical biology, May-04, Volume: 2, Issue:5
Inhibition studies of porphobilinogen synthase from Escherichia coli differentiating between the two recognition sites.
AID1799787Isothermal Titration Calorimetry from Article 10.1074/jbc.M110.110403: \\Identification of a chemoreceptor for tricarboxylic acid cycle intermediates: differential chemotactic response towards receptor ligands.\\2010The Journal of biological chemistry, Jul-23, Volume: 285, Issue:30
Identification of a chemoreceptor for tricarboxylic acid cycle intermediates: differential chemotactic response towards receptor ligands.
AID1799666Inhibition Assay from Article 10.1080/14756360109162375: \\Glycosylasparaginase inhibition studies: competitive inhibitors, transition state mimics, noncompetitive inhibitors.\\2001Journal of enzyme inhibition, , Volume: 16, Issue:3
Glycosylasparaginase inhibition studies: competitive inhibitors, transition state mimics, noncompetitive inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,987)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990838 (21.02)18.7374
1990's523 (13.12)18.2507
2000's851 (21.34)29.6817
2010's1272 (31.90)24.3611
2020's503 (12.62)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 86.75

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index86.75 (24.57)
Research Supply Index8.35 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index159.64 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (86.75)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials29 (0.69%)5.53%
Reviews166 (3.93%)6.00%
Case Studies22 (0.52%)4.05%
Observational1 (0.02%)0.25%
Other4,001 (94.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]